Research Ethics Committee in Sydney, Australia (#SVH15/227). Table 1. Patient Characteristics Through genome-wide interrogation of 7,472,833 biallelic single-nucleotide variants (SNVs), all patients were classified genetically as being of African
Search Results
Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer
Kazzem Gheybi, Jue Jiang, Shingai B.A. Mutambirwa, Pamela X.Y. Soh, Zsofia Kote-Jarai, Weerachai Jaratlerdsiri, Rosalind A. Eeles, M.S. Riana Bornman, and Vanessa M. Hayes
Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer
Eric M. Lander, Xuanyi Li, Li-Ching Huang, Amanda S. Cass, Wade T. Iams, Emily A. Skotte, Jennifer G. Whisenant, Robert A. Ramirez, Sally J. York, Travis J. Osterman, Jennifer A. Lewis, Christine M. Lovly, Yu Shyr, and Leora Horn
hospitalization: demographics (E.M. Lander), disease characteristics (E.A. Skotte, E.M. Lander), disease status at admission (E.A. Skotte, E.M. Lander), end-of-life services (E.M. Lander), admission information (E.M. Lander), and medication reconciliation (A
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population
Sofia Yi, Rutu A. Rathod, Vijaya Subbu Natchimuthu, Sheena Bhalla, Jessica L. Lee, Travis Browning, Joyce O. Adesina, Minh Do, David Balis, Juana Gamarra de Wiliams, Ellen Kitchell, Noel O. Santini, David H. Johnson, Heidi A. Hamann, Simon J. Craddock Lee, Amy E. Hughes, and David E. Gerber
throughout the county. An enterprise-wide electronic health record (EHR) system (Epic) allows electronic tracking of a wide array of patient characteristics and outcomes. 15 Since its inception in 2017, lung cancer screening at Parkland is generally
Use of Inpatient Palliative Care Services in Patients With Advanced Cancer Receiving Critical Care Therapies
Kah Poh Loh, Maya Abdallah, Meng-Shiou Shieh, Mihaela S. Stefan, Penelope S. Pekow, Peter K. Lindenauer, Supriya G. Mohile, Dilip Babu, and Tara Lagu
are reliably coded. Patient and Clinical Characteristics We collected demographics including age, sex, race, insurance provider, comorbidities (modified combined comorbidity score derived from the Elixhauser and Charlson comorbidity index
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non–Small Cell Lung Cancer
Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani
mortality data with results from published literature and the SEER database. Flatiron’s mortality data are estimated to have a sensitivity of 85% to 90%, specificity of 97% to 98%, and accuracy of 95% to 97%. 15 Baseline Characteristics Demographic and
Treatment of Stage IV Colon Cancer in the United States: A Patterns-of-Care Analysis
Xiang Gao, Amanda R. Kahl, Paolo Goffredo, Albert Y. Lin, Praveen Vikas, Imran Hassan, and Mary E. Charlton
2014. In addition to the traditional demographic and tumor characteristics collected by SEER, the SEER POC study collected additional variables in a sample of patients from various SEER registries. For stage IV colon cancer, these variables included the
Renal Cell Cancer: A Shift in Approaches for Treatment of Advanced Disease in the United States
Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff
regions. Currently, SEER covers approximately 28% of the US population. 7 Information for each patient in SEER is primarily obtained from hospital records and includes tumor characteristics, treatment, and select demographic characteristics. Given that
Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials
Brooke E. Wilson, Michelle B. Nadler, Alexandra Desnoyers, and Eitan Amir
anticancer therapy before documenting an event of interest can all result in informative censoring. 3 Differential censoring between the experimental and control arms may also introduce bias, especially if it results in differences in patient characteristics
Therapeutic Delays Lead to Worse Survival Among Patients With Hepatocellular Carcinoma
Amit G. Singal, Akbar K. Waljee, Nishant Patel, Emerson Y. Chen, Jasmin A. Tiro, Jorge A. Marrero, and Adam C. Yopp
greater than 200 ng/mL, or histologic confirmation for tumors larger than 1 cm. 20 Tumor characteristics were determined by imaging studies, which had all been interpreted by radiologists at the authors’ institution, and tumor staging was performed using
Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors
Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Elena Tolomio, Milena Sant, Gianpiero Castelli, Leonardo Zichichi, Giovanni Pellacani, Ignazio Stanganelli, Marco Simonacci, Ausilia Manganoni, Corrado Del Forno, Gioachino Caresana, Catherine Harwood, Daniele Bergamaschi, Konstantinos Lasithiotakis, Dorothy Bennett, Vittoria Espeli, Cristina Mangas, Sandra Leoni Parvex, Barbara Valeri, Mara Cossa, Marta Barisella, Alessandro Pellegrinelli, Claudia Miranda, Andrea Anichini, Roberta Mortarini, Odysseas Zoras, and Mario Santinami
completion lymph node dissection (CLND) as additional therapy. Statistical Methods Clinicopathologic characteristics were recorded according to SNB (performed vs not performed) for the whole series of patients, according to SN status (positive vs negative) in
